

House Bill 231

By: Representatives Broadrick of the 4th, Hawkins of the 27th, and Gravley of the 67th

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to change certain provisions relating to Schedules I, II, IV, and
3 V controlled substances; to change certain provisions relating to the definition of dangerous
4 drug; to provide for related matters; to provide for an effective date; to repeal conflicting
5 laws; and for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 **SECTION 1.**

8 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
9 substances, is amended in Code Section 16-13-25, relating to Schedule I controlled
10 substances, by adding a new subparagraph to paragraph (1) to read as follows:

11 "(RR) 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide (AH-7921);"

12 **SECTION 2.**

13 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
14 substances, by revising subparagraphs (CC), (EE), (JJ), (KK), (LL), (MM), (NN), (RR), and
15 (FFF) of and by adding new subparagraphs to paragraph (3) as follows:

16 "(CC) 3-methylfentanyl Reserved;"

17 "(EE) Para-fluorofentanyl Reserved;"

18 "(JJ) Alpha-Methylthiofentanyl Reserved;

19 (KK) Acetyl-Alpha-Methylfentanyl Reserved;

20 (LL) 3-Methylthiofentanyl Reserved;

21 (MM) Beta-Hydroxyfentanyl Reserved;

22 (NN) Thiofentanyl Reserved;"

23 "(RR) Beta-Hydroxy-3-Methylfentanyl Reserved;"

24 "(FFF) 4-Fluoromethcathinone Fluoromethcathinone;"

25 "(EEEE) 1-(1-benzofuran-6-yl)propan-2-amine (6-APB);"

26 (FFFF) 1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine (5-EAPB);"

27 **SECTION 3.**

28 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
29 substances, by revising subparagraphs (B) and (C) of paragraph (4) as follows:

30 "~~(B) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzyl-fentanyl) Reserved;~~

31 ~~(C) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thienylfentanyl)~~
32 Reserved;"

33 **SECTION 4.**

34 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
35 substances, by substituting the "." at the end of subparagraph (V) of paragraph (12) with a
36 ";," and by adding new paragraphs to read as follows:

37 "(13) The fentanyl analog structural class, including any of the following derivatives,
38 their salts, isomers, or salts of isomers, unless specifically utilized as part of the
39 manufacturing process by a commercial industry of a substance or material not intended
40 for human ingestion or consumption, as a prescription administered under medical
41 supervision, or for research at a recognized institution, whenever the existence of these
42 salts, isomers, or salts of isomers is possible within the specific chemical designation or
43 unless specifically excepted or listed in this or another schedule, structurally derived from
44 fentanyl, and whether or not further modified in any of the following ways:

45 (A) Substitution anywhere on the phenethyl group with:

46 (i) Alkyl group;

47 (ii) Hydroxyl group;

48 (iii) Halide group;

49 (B) Replacement of the phenethyl group with:

50 (i) Thienyl ethyl group, which can be further substituted with:

51 (I) Alkyl group;

52 (II) Hydroxyl group;

53 (III) Halide group;

54 (ii) Oxotetrazol ethyl group, which can be further substituted with:

55 (I) Alkyl group;

56 (II) Hydroxyl group;

57 (III) Halide group;

58 (iii) Alkyl group;

59 (iv) Thienyl methyl group, which can be further substituted with:

60 (I) Alkyl group;

- 61 (II) Hydroxyl group;
62 (III) Halide group;
63 (v) Benzyl group, which can be further substituted with:
64 (I) Alkyl group;
65 (II) Hydroxyl group;
66 (III) Halide group;
67 (vi) Furanyl ethyl group, which can be further substituted with:
68 (I) Alkyl group;
69 (II) Hydroxyl group;
70 (III) Halide group;
71 (vii) Phenyl alkyl group, which can be further substituted with:
72 (I) Alkyl group;
73 (II) Hydroxyl group;
74 (III) Halide group;
75 (viii) Pyridinyl ethyl group, which can be further substituted with:
76 (I) Alkyl group;
77 (II) Hydroxyl group;
78 (III) Halide group;
79 (ix) Diazole ethyl group, which can be further substituted with:
80 (I) Alkyl group;
81 (II) Hydroxyl group;
82 (III) Halide group;
83 (IV) Nitro group;
84 (x) Thiazole ethyl group, which can be further substituted with:
85 (I) Alkyl group;
86 (II) Hydroxyl group;
87 (III) Halide group;
88 (xi) Benzoxazolinone ethyl group, which can be further substituted with:
89 (I) Alkyl group;
90 (II) Hydroxyl group;
91 (III) Halide group;
92 (C) Substitution anywhere on the piperidine ring with:
93 (i) Alkyl group;
94 (ii) Allyl group;
95 (iii) Phenyl group;
96 (iv) Ester group;
97 (v) Ether group;

- 98 (vi) Pyridine group, which can be further substituted with:
99 (I) Alkyl group;
100 (II) Hydroxyl group;
101 (III) Halide group;
102 (vii) Thiazole group, which can be further substituted with:
103 (I) Alkyl group;
104 (II) Hydroxyl group;
105 (III) Halide group;
106 (viii) Oxadiazole group, which can be further substituted with:
107 (I) Alkyl group;
108 (II) Hydroxyl group;
109 (III) Halide group;
110 (IV) Ether group;
111 (D) Substitution anywhere on the propanamide group with:
112 (i) Cyclic alkyl group;
113 (ii) Acyclic alkyl group;
114 (iii) Methoxy group;
115 (E) Replacement of the propanamide group with:
116 (i) Acryloyl amino group;
117 (ii) Acetamide group, which itself can be further substituted with a cyclic alkyl
118 group;
119 (iii) Methoxy acetamide group;
120 (iv) Furanyl amide group;
121 (F) Substitution anywhere on the phenyl ring with:
122 (i) Halide group;
123 (ii) Methoxy group;
124 (iii) Alkyl group;
125 (G) Replacement of the phenyl ring with the pyrazine ring;
126 (14) The piperidinyl-sulfonamide structural class, including any of the following
127 compounds, derivatives, their salts, isomers, or salts of isomers, halogen analogues, or
128 homologues, unless specifically utilized as part of the manufacturing process by a
129 commercial industry of a substance or material not intended for human ingestion or
130 consumption, as a prescription administered under medical supervision, or for research
131 at a recognized institution, whenever the existence of these salts, isomers, or salts of
132 isomers, halogen analogues, or homologues is possible within the specific chemical
133 designation or unless specifically excepted or listed in this or another schedule,

134 structurally derived from piperidinyl-sulfonamide, and whether or not further modified
135 in any of the following ways:

136 (A) By substitution at the 1-position of the piperidinyl ring with any of the following:

137 (i) Alkyl group;

138 (ii) Phenyl alkyl group;

139 (iii) Amino substituted phenyl alkyl group;

140 (iv) Nitro substituted phenyl alkyl group;

141 (v) Cycloalkyl group;

142 (vi) Alkenyl substituent group;

143 (B) By substitution at the 3-position or 4-position of the piperidinyl ring with any of
144 the following:

145 (i) Halide group;

146 (ii) Alkyl group;

147 (iii) Alkoxy substituent;

148 (C) By substitution on the sulfonamide ring with any of the following:

149 (i) Pyridyl group;

150 (ii) Alkyl group;

151 (iii) Phenyl group;

152 (iv) Phenyl alkyl group;

153 (v) Alkoxy substituted phenyl group;

154 (vi) Halogen substituted phenyl group;

155 (vii) Nitro substituted phenyl group;

156 (viii) Amino substituted phenyl group;

157 (ix) Alkanoylamino substituted phenyl group;

158 (x) Amido substituted phenyl group;

159 (15) The 1-cyclohexyl-4-(1,2-diphenylethy)-piperazine (MT-45) structural class,
160 including any of the following derivatives, their salts, isomers, or salts of isomers, unless
161 specifically utilized as part of the manufacturing process by a commercial industry of a
162 substance or material not intended for human ingestion or consumption, as a prescription
163 administered under medical supervision, or for research at a recognized institution,
164 whenever the existence of these salts, isomers, or salts of isomers is possible within the
165 specific chemical designation or unless specifically excepted or listed in this or another
166 schedule, structurally derived from 1-cyclohexyl-4-(1,2-diphenylethy)-piperazine
167 (MT-45), and whether or not further modified in any of the following ways:

168 (A) Replacement of the cyclohexyl group with any of the following:

169 (i) Cycloheptyl group;

170 (ii) Cyclooctyl group;

171 (B) Substitution on the diphenyl groups with any of the following:

172 (i) Hydroxyl group;

173 (ii) Halide;

174 (iii) Alkoxy group;

175 (iv) Alkyl group;

176 (v) Ester group;

177 (vi) Phenyl ether group."

178 **SECTION 5.**

179 Said chapter is further amended in Code Section 16-13-26, relating to Schedule II controlled
180 substances, by adding new subparagraphs to paragraph (2) to read as follows:

181 "(C.5) Carfentanil;"

182 "(V.2) Thiafentanil;"

183 **SECTION 6.**

184 Said chapter is further amended in Code Section 16-13-26, relating to Schedule II controlled
185 substances, by revising subparagraph (E) of paragraph (3) as follows:

186 "(E) ~~Carfentanil~~ Reserved;"

187 **SECTION 7.**

188 Said chapter is further amended in Code Section 16-13-28, relating to Schedule IV controlled
189 substances, by revising paragraph (1) of subsection (b) as follows:

190 "(1) By substitution at the 2-position with a ketone or a thione;"

191 **SECTION 8.**

192 Said chapter is further amended in Code Section 16-13-29, relating to Schedule V controlled
193 substances, by striking "or" at the end of paragraph (5), by substituting the "." at the end of
194 paragraph (6) with a ";", and by adding a new paragraph to read as follows:

195 "(7) Brivaracetam."

196 **SECTION 9.**

197 Said chapter is further amended in Code Section 16-13-71, relating to the definition of a
198 dangerous drug, by adding new paragraphs to subsection (b) to read as follows:

199 "(13.531) Adalimumab-atto;"

200 "(68.13) Atezolizumab;"

201 "(97.4) Bezlotoxumab;"

202 "(217.4) Crisaborole;"

203 "(244.2) Defibrotide;"
 204 "(331.053) Elbasvir;"
 205 "(355.6) Etanercept-szsz;"
 206 "(355.8) Eteplirsen;"
 207 "(430.7) Grazoprevir;"
 208 "(472.51) Infliximab-dyyb;"
 209 "(506.97) Ixekizumab;"
 210 "(520.2) Lifitegrast;"
 211 "(528.1) Lixisenatide;"
 212 "(658.7) Nusinersen;"
 213 "(661.03) Obeticholic acid;"
 214 "(661.05) Obiltoxaximab;"
 215 "(661.96) Olaratumab;"
 216 "(663.36) Omalizumab;"
 217 "(663.6) OnabotulinumtoxinA;"
 218 "(769.37) Prasterone;"
 219 "(835.5) Reslizumab;"
 220 "(848.2) Rucaparib;"
 221 "(1027.53) Velpatasvir;"
 222 "(1027.57) Venetoclax;"

223 **SECTION 10.**

224 Said chapter is further amended in Code Section 16-13-71, relating to the definition of a
 225 dangerous drug, by revising paragraphs (13.55), (198.05), and (673) of subsection (b) as
 226 follows:

227 "(13.55) Adapalene — See exceptions;"
 228 "~~(198.05) Clobazam;~~"
 229 "(673) Reserved Oxymetazoline;"

230 **SECTION 11.**

231 Said chapter is further amended in Code Section 16-13-71, relating to the definition of a
 232 dangerous drug, by adding a new paragraph to subsection (c) to read as follows:

233 "(0.5) Adapalene — when used with a strength up to 0.1 percent in a topical skin
 234 product;"

235 **SECTION 12.**

236 This Act shall become effective upon its approval by the Governor or upon its becoming law
237 without such approval.

238 **SECTION 13.**

239 All laws and parts of laws in conflict with this Act are repealed.